About Us
Alexion is a global
biopharmaceutical company that combines groundbreaking science with a steadfast
commitment to meeting the needs of patients living with severe, life-threatening
and often ultra-rare
diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.
Alexion discovered and developed Soliris® (eculizumab),
a first-in-class terminal complement inhibitor approved in the United States, European
Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal
hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional
biopharmaceuticals as treatments for patients with other rare and severe diseases,
including cancer.